- Home
- BTAI vs TACT Comparison
BTAI vs TACT Comparison
Compare BTAI & TACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- TACT
- Stock Information
- Founded
- BTAI 2017
- TACT 1996
- Country
- BTAI United States
- TACT United States
- Employees
- BTAI N/A
- TACT N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- TACT Computer peripheral equipment
- Sector
- BTAI Health Care
- TACT Technology
- Exchange
- BTAI Nasdaq
- TACT Nasdaq
- Market Cap
- BTAI 52.7M
- TACT 42.2M
- IPO Year
- BTAI 2018
- TACT 1996
- Fundamental
- Price
- BTAI $3.01
- TACT $4.61
- Analyst Decision
- BTAI Buy
- TACT Strong Buy
- Analyst Count
- BTAI 5
- TACT 1
- Target Price
- BTAI $32.80
- TACT $5.00
- AVG Volume (30 Days)
- BTAI 5.2M
- TACT 79.6K
- Earning Date
- BTAI 11-13-2025
- TACT 11-06-2025
- Dividend Yield
- BTAI N/A
- TACT N/A
- EPS Growth
- BTAI N/A
- TACT N/A
- EPS
- BTAI N/A
- TACT N/A
- Revenue
- BTAI $868,000.00
- TACT $47,949,000.00
- Revenue This Year
- BTAI N/A
- TACT $21.67
- Revenue Next Year
- BTAI $614.78
- TACT $7.63
- P/E Ratio
- BTAI N/A
- TACT N/A
- Revenue Growth
- BTAI N/A
- TACT N/A
- 52 Week Low
- BTAI $1.17
- TACT $3.12
- 52 Week High
- BTAI $13.28
- TACT $4.90
- Technical
- Relative Strength Index (RSI)
- BTAI 41.66
- TACT 65.34
- Support Level
- BTAI $2.86
- TACT $4.54
- Resistance Level
- BTAI $3.95
- TACT $4.89
- Average True Range (ATR)
- BTAI 0.34
- TACT 0.18
- MACD
- BTAI -0.17
- TACT -0.00
- Stochastic Oscillator
- BTAI 11.89
- TACT 75.67
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.